Silexion shareholders reject 175M-share capital increase and 1-for-15 reverse split

Silexion Therapeutics Corp

• Proposal 1 to increase authorized capital by 175,000,000 ordinary shares, to US$25,771,500 divided into 190,900,000 shares, failed: 24.6% in favor, 75.4% against, 27,003 abstentions.
• Proposal 2 to authorize a 1-for-15 reverse share split of all issued, outstanding and unissued ordinary shares failed: 25.9% in favor, 74.1% against.
• Neither proposal received a simple majority of shareholders present, so neither was approved at the reconvened extraordinary general meeting.
• Meeting originally scheduled September 9, 2026, adjourned twice for lack of quorum, then reconvened September 23, 2026 with 2,208,353 shares (about 36.8% of issued and outstanding) present.
• After a half hour without a quorum, the shareholders present constituted a quorum under Article 21.3 of the amended and restated articles of association.